The abstract is read at the publisher; the summary is JClub's.
Nontargeted HCV screening in US emergency departments is cost-effective, curing 65.89% of infections with an ICER of $12 820 per QALY gained in the base case simulation.
- Why it matters: ED-based HCV screening can outperform targeted approaches clinically, but decision-makers still need evidence on lifetime cost-effectiveness to choose between strategies.
- What they did: Using DETECT Hep C trial inputs, the HEP-CE model simulated three ED strategies—no screening, targeted screening, and nontargeted screening—over a lifetime horizon from a health sector perspective using Denver Health, Johns Hopkins, and University of Mississippi Medical Center data.
- The result: Compared with nontargeted screening, no screening and targeted screening cured fewer infections (65.60% and 65.88%) with nearly identical discounted costs ($214 467 and $214 462) and QALYs, implying clear value mainly among those living with HCV infection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.